Comparison of the SARS-CoV-2 spike protein ELISA and the Abbott Architect SARS-CoV-2 IgG nucleocapsid protein assays for detection of antibodies.
cross_sectional · Level IV
Where this comes from
- Record sourced from PubMed, PMID 34324576.
- Also identified by DOI 10.1371/journal.pone.0255208 and PMC identifier 8320896.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Serologic assays developed for SARS-CoV-2 detect different antibody subtypes and are based on different target antigens. Comparison of the performance of a SARS-CoV-2 Spike-Protein ELISA and the nucleocapsid-based Abbott ArchitectTM SARS-CoV-2 IgG assay indicated that the assays had high concordance, with rare paired discordant tests results.
Medical subject headings
- Antibodies, Viral
- COVID-19
- Immunoglobulin G
- Nucleocapsid
- Nucleocapsid Proteins
- SARS-CoV-2
- Spike Glycoprotein, Coronavirus